Circulating tumor signaling molecules Wnt/β-catenin and WISP1, IL-8 as prognostic biomarkers in ovarian cancer
- 作者: Abakumova T.V.1, Dolgova D.R.1, Antoneeva I.I.1,2, Myagdieva I.R.1, Gening S.O.3, Gening T.P.1, Burkhanova E.V.1
-
隶属关系:
- Ulyanovsk State University
- Regional Clinical Oncology Center
- Luchi Zdorovye LLC
- 期: 卷 28, 编号 3 (2025)
- 页面: 797-804
- 栏目: SHORT COMMUNICATIONS
- URL: https://journal-vniispk.ru/1028-7221/article/view/319937
- DOI: https://doi.org/10.46235/1028-7221-17091-CTS
- ID: 319937
如何引用文章
全文:
详细
Experimental data suggest a role for Wnt/β-catenin signaling in ovarian cancer progression and chemotherapy resistance. Development of a prognostic model for ovarian cancer outcomes based on circulating Wnt signaling molecules will allow staging of advanced ovarian cancer and assessment of metastasis risk. The aim of our study was to evaluate prognostic significance of circulating Wnt signaling molecules (β-catenin and WISP1, IL-8) in advanced ovarian cancer. The levels of IL-8, β-catenin and WISP1 (pg/mL) were assessed by ELISA technique in blood plasma of 30 primary patients with advanced ovarian cancer stage III-IV according to FIGO scale. All patients were divided into groups: I, platinum-resistant; II, platinum-sensitive. The control included plasma samples from somatically healthy women. Statistical processing was carried out using Statistica 13. Analysis of progression-free time was carried out using the Cox regression method, and the patient survival was assessed using the Kaplan–Meier method. A cutoff point was defined to assess categories based on the values used for prediction (Jamovi 2.4.14). A significant increase in β-catenin level against control was revealed at stages III and IV of malignant disease. However, no significant differences depending on sensitivity to standard chemotherapy were found for the studied parameters. The Cox model enabled us to estimate the risk of developing stage IV ovarian cancer based on β-catenin level in blood plasma (p = 0.033). Moreover, the risk of progression to stage IV ovarian cancer increases with elevation of both β-catenin (>28.1) and WISP1 levels (>445) in blood plasma (R2 = 0.451, χ2 = 28.4, p = 0.001). A sharp increase in serum IL-8 levels was found at stage IV (cutoff-point = 87.3, p = 0.001), and the median progression-free time was 9.8 months [95% CI 8.1-14]. Upon increase in circulating IL-8 by 1 pg/ml, the odds ratio increases by 1.02 (p < 0.001). Hence, the established levels of circulating IL-8 and β-catenin in blood plasma may be considered prognostic factors for assessing progression of ovarian cancer. Meanwhile, for discerning stage III-IV ovarian cancer, a joint statistical significance was shown for β-catenin and WISP-1 in blood plasma.
作者简介
Tatyana Abakumova
Ulyanovsk State University
编辑信件的主要联系方式.
Email: taty-abakumova@yandex.ru
ORCID iD: 0000-0001-7559-5246
PhD, MD (Biology), Associate Professor, Professor, S.P. Kapitsa Research Technological Institute, Department of Physiology and Pathophysiology, Senior Researcher, S. Kapitsa Research Technological Institute
俄罗斯联邦, UlyanovskDinara Dolgova
Ulyanovsk State University
Email: dolgova.dinara@yandex.ru
ORCID iD: 0000-0001-5475-7031
PhD (Biology), Associate Professor, Department of Physiology and Pathophysiology, Senior Researcher, Director, Research Medical and Biological Center, S. Kapitsa Research Technological Institute
俄罗斯联邦, UlyanovskInna Antoneeva
Ulyanovsk State University; Regional Clinical Oncology Center
Email: aii72@mail.ru
ORCID iD: 0000-0002-1525-2070
PhD, MD (Medicine), Professor, Department of Physiology and Pathophysiology, Head of the Department of Oncogynecology
俄罗斯联邦, Ulyanovsk; UlyanovskIlseya Myagdieva
Ulyanovsk State University
Email: Ilseya2015@yandex.ru
ORCID iD: 0000-0002-3908-0840
Junior Researcher, Department of Physiology and Pathophysiology, Junior Researcher, S. Kapitsa Research Technological Institute
俄罗斯联邦, UlyanovskSnezhanna Gening
Luchi Zdorovye LLC
Email: sgening@bk.ru
ORCID iD: 0000-0001-6970-6659
PhD (Medicine), Oncologist
俄罗斯联邦, MoscowTatyana Gening
Ulyanovsk State University
Email: Naum-53@yandex.ru
ORCID iD: 0000-0002-5117-1382
PhD, MD (Biology), Professor, Head, Department of Physiology and Pathophysiology
俄罗斯联邦, UlyanovskElizaveta Burkhanova
Ulyanovsk State University
Email: burkhanova_e@inbox.ru
ORCID iD: 0009-0008-6955-9204
Student, Faculty of Medicine
俄罗斯联邦, Ulyanovsk参考
- Chang A.C., Lin L.W., Chen Y.C., Chen P.C., Liu S.C., Tai H.C., Wu H.-C., Sung S.-Y., Lin T.-H., Tang C.-H. The ADAM9/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis // Int. J. Biol. Sci., 2023, Vol. 19, no. 3, pp. 760-771.
- Duan L., Yang Q., Yang J., Hu Q., Wang B., Li P., Chen W. Identification of serum β-catenin as a biomarker in patients with HBV-related liver diseases. J. Transl. Med., 2018, Vol. 16, no. 1, 265. doi: 10.1186/s12967-018-1645-x.
- Gonzalez M.E., Brophy B., Eido A., Leonetti A.E., Djomehri S.I., Augimeri G., Carruthers N.J., Cavalcante R.G., Giordano F., Andò S., Nesvizhskii A.I., Fearon E.R., Kleer C.G. CCN6 suppresses metaplastic breast carcinoma by antagonizing Wnt/β-сatenin signaling to Inhibit EZH2-Driven EMT. Cancer Res., 2024, Vol. 84, no. 19, pp. 3235-3249.
- Graumann J., Finkernagel F., Reinartz S., Stief T., Brödje D., Renz H., Jansen J.M., Wagner U., Worzfeld T., von Strandmann E.P., Müller R. Multi-platform affinity proteomics identify proteins linked to metastasis and immune suppression in ovarian cancer plasma. Front. Oncol., 2019, Vol. 9, 1150. doi: 10.3389/fonc.2019.01150.
- Huang J., Zhou Y., Xiao W., Deng P., Wei Q., Lu W. Serum β-catenin changes vary among different stages of osteonecrosis of the femoral head: an exploratory biomarker study. BMC Musculoskelet. Disord., 2022, Vol. 23, no. 1, 434. doi: 10.1186/s12891-022-05399-2.
- Kalbasi A., Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol., 2020, Vol. 20, pp. 25-39.
- Li S., Huang M., Liu Q., Wang D., Wu R., Zhang X., Chen W., Duan L. Serum Expression of β-catenin is a potential detection marker in patients with colorectal cancer. Dis. Markers, 2019, Vol. 2019, 5070524. doi: 10.1155/2019/5070524
- Li Y., Wang F., Liu T., Lv N., Yuan X., Li P. WISP1 induces ovarian cancer via the IGF1/αvβ3/Wnt axis. J. Ovarian Res., 2022, Vol. 15, no. 1, 94. doi: 10.1186/s13048-022-01016-x.
- Liu Y., Li W., Luo J., Wu Y., Xu Y., Chen T., Zhang W., Fu F. Cysteine-rich intestinal protein 1 served as an epithelial ovarian cancer marker via promoting Wnt/β-catenin-mediated EMT and tumour metastasis. Dis. Markers, 2021, Vol. 2021, 3566749. doi: 10.1155/2021/3566749.
- Matulonis U.A., Shapira-Frommer R., Santin A.D., Lisyanskaya A.S., Pignata S., Vergote I., Raspagliesi F., Sonke G.S., Birrer M., Provencher D.M., Sehouli J., Colombo N., González-Martín A., Oaknin A., Ottevanger P.B., Rudaitis V., Katchar K., Wu H., Keefe S., Ruman J., Ledermann J.A. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol., 2019, Vol. 30, no. 7, pp. 1080-1087.
- Nelson W.J. The Glue that binds us: the hunt for the molecular basis for multicellularity. Cell, 2020, Vol. 181, no. 3, pp. 495-497.
- Reddy S.U., Sadia F.Z., Vancura A., Vancurova I. IFNγ-Induced Bcl3, PD-L1 and IL-8 signaling in ovarian cancer: mechanisms and clinical significance. Cancers (Basel), 2024, Vol. 16, no. 15, 2676. doi: 10.3390/cancers16152676.
- Teeuwssen M., Fodde R. Wnt signaling in ovarian cancer stemness, EMT, and therapy resistance. J. Clin. Med., 2019. Vol. 8, no. 10, 1658. doi: 10.3390/jcm8101658.
补充文件
